^
    Back
    Association details:
    Biomarker:TSC1 deletion
    Cancer:Urothelial Cancer
    Drug:buparlisib (AN2025) (PI3K inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer
    Title:

    A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma

    Published date:
    08/07/2020
    Excerpt:
    Buparlisib was found to demonstrate modest activity in patients with metastatic UC whose tumors harbored TSC1 loss of function alterations…
    DOI:
    10.1002/cncr.33071